Wells Fargo & Company MN grew its position in Insys Therapeutics, Inc. (NASDAQ:INSY) by 0.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 27,667 shares of the specialty pharmaceutical company’s stock after buying an additional 126 shares during the period. Wells Fargo & Company MN’s holdings in Insys Therapeutics were worth $350,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in INSY. SG Americas Securities LLC bought a new stake in Insys Therapeutics in the 2nd quarter valued at $138,000. American International Group Inc. lifted its position in Insys Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after acquiring an additional 953 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in Insys Therapeutics by 213.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock valued at $166,000 after acquiring an additional 8,940 shares in the last quarter. UBS Asset Management Americas Inc. bought a new stake in Insys Therapeutics in the 1st quarter valued at $172,000. Finally, State of Wisconsin Investment Board bought a new stake in Insys Therapeutics in the 2nd quarter valued at $240,000. 25.23% of the stock is owned by institutional investors.

Shares of Insys Therapeutics, Inc. (NASDAQ INSY) opened at $5.29 on Friday. Insys Therapeutics, Inc. has a 52-week low of $4.10 and a 52-week high of $15.02.

Several equities research analysts recently commented on INSY shares. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Insys Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Jefferies Group LLC cut their price objective on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. TheStreet cut shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, August 21st. Finally, BidaskClub cut shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $9.38.

TRADEMARK VIOLATION WARNING: “Insys Therapeutics, Inc. (INSY) Shares Bought by Wells Fargo & Company MN” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/insys-therapeutics-inc-insy-shares-bought-by-wells-fargo-company-mn/1708659.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics, Inc. (NASDAQ:INSY).

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.